NEW YORK CITY, NEW YORK / ACCESS Newswire / October 30, 2025 / TruMerit President and CEO Peter Preziosi has been elected ...
LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 30, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into ...
Medidata Consent, a key part of the Medidata Patient Experience, expedites study start-up, reduces configuration complexity, and improves patient enrollment New York – Oct. 30, 2025 – Medidata, a ...
Former Inizio Evoke President of CX joins Supreme Group’s management team to lead platform-wide growth strategy WEST CHESTER, Pa. — Oct. 30, 2025 — Supreme Group, a next-generation agency platform ...
Physician-led wellness brand brings its evidence-based longevity and recovery model to downtown LA. LOS ANGELES, CA / ACCESS ...
AGFA HealthCare will highlight what truly drives transformation in medical imaging: clinicians. CARLSTADT, NEW JERSEY / ACCESS Newswire / October 30, 2025 / While technology enables progress, AGFA ...
MESA, ARIZONA / ACCESS Newswire / October 30, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a diversified holding company operating at the intersection of technology, wellness, and ...
NEW YORK, NY / ACCESS Newswire / October 30, 2025 / In the face of growing global concern over the potential use of chemical weapons such as the nerve agent Sarin, Lunai Bioworks Inc. (NASDAQ:LNAI) ...
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics (NASDAQ:ENTO) has just made one of the boldest moves in its history, a reinvention that trades long biotech timelines for ...
ATLANTA, GA / ACCESS Newswire / October 30, 2025 / Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development‐stage biotechnology company developing new medicines to treat pain and ...
Boehringer Ingelheim licences a novel small-molecule treatment from Kyowa Kirin for fibro-inflammatory and autoimmune diseases in a deal worth up to €410 million.
Novo Nordisk has topped Pfizer’s offer for Metsera with a bid of up to US$9 billion, seeking to secure Metsera’s obesity-drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback